{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:02:24Z","timestamp":1772640144916,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.drudis.2022.05.015","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T21:08:28Z","timestamp":1652908108000},"page":"2440-2466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Benjamin","family":"Micallef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Nistico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan Bardakci","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Serracino-Inglott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Joseph","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.drudis.2022.05.015_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ctrv.2010.02.003","article-title":"Epidemiology of childhood cancer","volume":"36","author":"Kaatsch","year":"2010","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0010","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"10.1016\/j.drudis.2022.05.015_b0015","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995\u20132009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0020","first-page":"156","article-title":"Advances in paediatric cancer treatment","volume":"3","author":"Saletta","year":"2014","journal-title":"Transl Pediatr."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0025","first-page":"212","article-title":"Improving the outcome for children with cancer: development of targeted new agents","volume":"65","author":"Adamson","year":"2015","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"Kato","year":"2018","journal-title":"Pediatr Int."},{"issue":"21","key":"10.1016\/j.drudis.2022.05.015_b0035","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol."},{"issue":"5","key":"10.1016\/j.drudis.2022.05.015_b0045","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.drudis.2022.01.002","article-title":"The changing landscape of treatment options in childhood acute lymphoblastic leukaemia","volume":"27","author":"Micallef","year":"2022","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.drudis.2022.05.015_b0050","unstructured":"European Medicines Agency. www.ema.europa.eu\/en\/medicines\/download-medicine-data Accessed May 16, 2022."},{"issue":"4","key":"10.1016\/j.drudis.2022.05.015_b0055","first-page":"1121","article-title":"Clinical endpoints in oncology \u2013 a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviscsurg.2013.10.001","article-title":"Endpoints in cancer clinical trials","volume":"151","author":"Fiteni","year":"2014","journal-title":"J Visc Surg."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2016.1257606","article-title":"Emerging biological therapies to treat acute lymphoblastic leukemia","volume":"22","author":"Huguet","year":"2017","journal-title":"Expert Opin Emerg Drugs."},{"key":"10.1016\/j.drudis.2022.05.015_b0070","unstructured":"The European Parliament and the Council of Europe. Directive 2001\/83\/EC of the European parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. OJ. 2001; L311: 67\u2013129."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jsps.2016.07.005","article-title":"Changing paradigms in bioequivalence trials submitted to the EMA for evaluation \u2013 a clinical and regulatory perspective","volume":"25","author":"Refalo","year":"2017","journal-title":"Saudi Pharm J."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1208\/s12249-017-0892-0","article-title":"Quality issues identified during the evaluation of biosimilars by the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use","volume":"19","author":"Cilia","year":"2018","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.drudis.2022.05.015_b9000","unstructured":"European Medicines Agency. EU Clinical Trials Register. https:\/\/www.clinicaltrialsregister.eu\/. Accessed Jul 14, 2021."},{"key":"10.1016\/j.drudis.2022.05.015_b0090","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov Accessed May 16, 2022."},{"key":"10.1016\/j.drudis.2022.05.015_b0095","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Glivec-H-C-406-II-0031: EPAR \u2013 Scientific Discussion \u2013 Variation. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/glivec-h-c-406-ii-0031-epar-scientific-discussion-variation_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0100","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Glivec-H-C-406-II-0080: EPAR \u2013 Assessment Report \u2013 Variation \u2013 EMA\/CHMP\/161314\/2013. European Medicines Agency. www.ema.europa.eu\/en\/documents\/variation-report\/glivec-h-c-406-ii-0080-epar-assessment-report-variation_en.pdf. Published 2013 [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0105","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Atriance Scientific Discussion. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-discussion\/atriance-epar-scientific-discussion_en.pdf. Published 2007 [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0110","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Sprycel Scientific Discussion. European Medicines Agency website. www.ema.europa.eu\/en\/documents\/scientific-discussion\/sprycel-epar-scientific-discussion_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0115","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Sprycel Assessment report \u2013 EMA\/CHMP\/3851\/2019. European Medicines Agency. www.ema.europa.eu\/en\/documents\/variation-report\/sprycel-h-c-709-ii-0059-epar-assessment-report-variation_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0120","unstructured":"European Medicines Agency (EMA). EMEA-000567-PIP01-09-M05. www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-000567-pip01-09-m05 [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0125","unstructured":"Committee for Medicinal Products for Human Use (CHMP). CHMP Assessment Report Mercaptopurine Nova Laboratories \u2013 EMA\/CHMP\/668488\/2011. European Medicines Agency. [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0130","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report Jylamvo \u2013 EMA\/78284\/2017. European Medicines Agency website. www.ema.europa.eu\/en\/documents\/assessment-report\/jylamvo-epar-public-assessment-report_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0135","unstructured":"Committee for Medicinal Products for Human Use (CHMP) and Paediatric Committee (PDCO). Guideline on Pharmaceutical Development of Medicines for Paediatric Use \u2013 EMA\/CHMP\/QWP\/805880\/2012 Rev. 2. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0140","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence \u2013 CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr*. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0145","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment Report Tepadina \u2013 EMA\/CHMP\/55233\/2010. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tepadina-epar-public-assessment-report_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0150","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Busilvex\u00ae (Busulfan) EPAR \u2013 Scientific Discussion. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-discussion\/busilvex-epar-scientific-discussion_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0155","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Busilvex-H-C-472-II-04: EPAR \u2013 Scientific Discussion \u2013 Variation. European Medicines Agency. www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/busilvex-h-c-472-ii-04-epar-scientific-discussion-variation_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0160","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report Trecondi \u2013 EMA\/903773\/2019. European Medicines Agency. www.ema.europa.eu\/en\/documents\/assessment-report\/trecondi-epar-public-assessment-report_en.pdf [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0165","unstructured":"Ad Hoc Group for the development of Implementing Guidelines for Directive 2001\/20\/EC Relating to Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population. https:\/\/ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-10\/ethical_considerations_en.pdf [Accessed May 16, 2022]."},{"issue":"4","key":"10.1016\/j.drudis.2022.05.015_b0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrclinonc.2012.22","article-title":"Drug development and clinical trials\u2013the path to an approved cancer drug","volume":"9","author":"Rubin","year":"2012","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-018-0389-8","article-title":"Design considerations for early-phase clinical trials of immune-oncology agents","volume":"6","author":"Wages","year":"2018","journal-title":"Journal for ImmunoTherapy of Cancer."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","article-title":"The changing landscape of phase I trials in oncology","volume":"13","author":"Wong","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"10.1016\/j.drudis.2022.05.015_b0185","first-page":"49","article-title":"Adaptive clinical trial designs in oncology","volume":"3","author":"Zang","year":"2014","journal-title":"Chin Clin Oncol."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0190","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1878-0261.12465","article-title":"New clinical trial designs in the era of precision medicine","volume":"13","author":"Garralda","year":"2019","journal-title":"Mol Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin Transl Sci."},{"issue":"5","key":"10.1016\/j.drudis.2022.05.015_b0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/10543406.2014.920873","article-title":"Seamless Phase I\/II adaptive design for oncology trials of molecularly targeted agents","volume":"25","author":"Wages","year":"2015","journal-title":"J Biopharm Stat."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0205","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/annonc\/mdx795","article-title":"Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding","volume":"29","author":"Yan","year":"2018","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1016\/j.drudis.2022.05.015_b0210","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","article-title":"Early phase clinical trials to identify optimal dosing and safety","volume":"9","author":"Cook","year":"2015","journal-title":"Mol Oncol."},{"issue":"17","key":"10.1016\/j.drudis.2022.05.015_b0215","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","article-title":"Immuno-oncology trial endpoints: capturing clinically meaningful activity","volume":"23","author":"Anagnostou","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0220","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdy002","article-title":"Joint adolescent\u2013adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform\u2014ACCELERATE","volume":"29","author":"Gaspar","year":"2018","journal-title":"Annals of Oncology."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-16-1367","article-title":"Enrolling adolescents in disease\/target-appropriate adult oncology clinical trials of investigational agents","volume":"23","author":"Chuk","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.drudis.2022.05.015_b0230","unstructured":"Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics \u2013 Guidance for Industry. FDA. www.fda.gov\/media\/71195\/download [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0235","unstructured":"European Medicines Agency (EMA). Guideline on the Evaluation of Anticancer Medicinal Products in Man. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf [Accessed May 16, 2022]."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol."},{"issue":"7","key":"10.1016\/j.drudis.2022.05.015_b0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcph.1109","article-title":"Primary endpoints in pediatric efficacy trials submitted to the US FDA","volume":"58","author":"Green","year":"2018","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomised trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"JCO."},{"issue":"6","key":"10.1016\/j.drudis.2022.05.015_b0255","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41375-019-0670-y","article-title":"Randomised post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial","volume":"34","author":"Attarbaschi","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.015_b0260","doi-asserted-by":"crossref","first-page":"pky069","DOI":"10.1093\/jncics\/pky069","article-title":"Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia","volume":"2","author":"Galimberti","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0285","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0290","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2020.06.003","article-title":"Monitoring MRD in ALL: methodologies, technical aspects and optimal time points for measurement","volume":"57","author":"Bartram","year":"2020","journal-title":"Semin Hematol."},{"key":"10.1016\/j.drudis.2022.05.015_b0300","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment Report Kymriah \u2013 EMA\/485563\/2018. EMA website. www.ema.europa.eu\/en\/documents\/assessment-report\/kymriah-epar-public-assessment-report_en.pdf [Accessed May 16, 2022]."},{"issue":"1","key":"10.1016\/j.drudis.2022.05.015_b0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"2010","journal-title":"J Exp Stroke Transl Med."},{"key":"10.1016\/j.drudis.2022.05.015_b0310","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Appendix 4 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man \u2013 EMA\/CHMP\/703715\/2012 Rev. 2. EMA. www.ema.europa.eu\/en\/documents\/scientific-guideline\/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-rev2_en.pdf. Published Dec 17, 2015 [Accessed May 16, 2022]."},{"issue":"8","key":"10.1016\/j.drudis.2022.05.015_b0315","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bmt.2014.78","article-title":"Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts","volume":"49","author":"Aljurf","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.drudis.2022.05.015_b0320","unstructured":"European Medicines Agency (EMA). Qualification opinion on cellular therapy module of the European Society for Blood and Marrow Transplantation (EBMT) registry. EMA. www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt_en.pdf [Accessed May 16, 2022]."},{"issue":"2","key":"10.1016\/j.drudis.2022.05.015_b0325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14740338.2022.1993820","article-title":"Improving the data quality of spontaneous ADR reports: a practical example from Malta","volume":"21","author":"Zuccarelli","year":"2022","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.drudis.2022.05.015_b0340","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.phrs.2018.10.014","article-title":"Optimising bench science to withstand regulatory scrutiny","volume":"139","author":"Borg","year":"2019","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.drudis.2022.05.015_b0345","unstructured":"European Medicines Agency (EMA). PRIME: Priority Medicines. The Netherlands: EMA. www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines [Accessed May 16, 2022]."},{"issue":"7","key":"10.1016\/j.drudis.2022.05.015_b0350","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S1470-2045(17)30442-4","article-title":"From class waivers to precision medicine in paediatric oncology","volume":"18","author":"Pearson","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002520","article-title":"Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: a cohort study","volume":"15","author":"Hwang","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.drudis.2022.05.015_b0360","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.clinthera.2019.10.006","article-title":"Orphan medicines for pediatric use: a focus on the European Union","volume":"41","author":"Bolislis","year":"2019","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.drudis.2022.05.015_b0365","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2168479017696265","article-title":"Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States","volume":"51","author":"Penkov","year":"2017","journal-title":"Ther Innov Regul Sci."},{"key":"10.1016\/j.drudis.2022.05.015_b0370","unstructured":"European Medicines Agency (EMA). Paediatric investigation plans: questions and answers. www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/paediatric-investigation-plans\/paediatric-investigation-plans-questions-answers [Accessed May 16, 2022]."},{"key":"10.1016\/j.drudis.2022.05.015_b0375","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2017.07.021","article-title":"Orphan Drug Regulation: a missed opportunity for children and adolescents with cancer","volume":"84","author":"Vassal","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.drudis.2022.05.015_b0380","unstructured":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. OJ 2006; L378; 1\u201319."},{"key":"10.1016\/j.drudis.2022.05.015_b0385","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. OJ 2000; L18; 1\u20135."},{"key":"10.1016\/j.drudis.2022.05.015_b0390","unstructured":"European Commission. Evaluation of the legislation on medicines for children and rare diseases (medicines for special populations). https:\/\/ec.europa.eu\/info\/law\/better-regulation\/have-your-say\/initiatives\/1248-Evaluation-of-the-legislation-on-medicines-for-children-and-rare-diseases-medicines-for-special-populations-_en [Accessed May 16, 2022]."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:59:04Z","timestamp":1761224344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622002069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1359644622002069"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.015","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}